CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
High Dose Device +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00824720
NCT00824720Phase 2Completed

Safety and Efficacy of a Glaucoma Drug Delivery System

Vistakon Pharmaceuticals·interventional·Posted Jan 19, 2009·Updated Mar 6, 2015

In Brief

A Phase 2 clinical trial evaluating High Dose Device, Low Dose Device, and 1 other intervention for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 55 participants across 4 sites.

Detailed Summary

The purpose of this study is to evaluate the ocular safety and efficacy of a glaucoma drug delivery system in open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 19, 2009
Enrollment StartDec 1, 2008
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 17.5 years ago

Interventions

High Dose Devicedrug

inserted for 14 days

Low Dose Devicedrug

inserted for 14 days

Placebo Devicedevice

inserted for 14 days